Biosimilar Name Debate Heats Up As USP Says Zarxio Doesn't Need Suffix

Determination that Zarxio meets monograph standards indicates product should carry same nonproprietary name as Neupogen, USP argues; FDA says monograph doesn't apply.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from United States

More from North America